Menu Back toCommunity Discussion of Data Science in Relation to Drug Development

DIA/FDA Biostatistics Industry and Regulator Forum

This event is now offered in a new entirely virtual format.

Community Discussion of Data Science in Relation to Drug Development

Session Chair(s)

Ruthie  Davi, PhD, MS

Ruthie Davi, PhD, MS

  • Vice President, Data Science and Statistician
  • Medidata, a Dassault Systèmes company, United States
Stella C. Grosser, PhD, MS

Stella C. Grosser, PhD, MS

  • Division Director, Office of Biostatistics, OTS, CDER
  • FDA, United States
This will be a community discussion of data science. Several panelists with experience in the area will be available to share their knowledge.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify common issues in the overlap between data science, statistics, and drug development
  • Describe examples where data science has impacted pharmaceuticals
  • Identify techniques of data science to possibly improve the efficiency of drug development


Nareen  Katta, MBA, MS


Nareen Katta, MBA, MS

  • Senior Director and Head of Clinical Analytics
  • Abbvie, United States
Paul  Schuette, PhD, MA


Paul Schuette, PhD, MA

  • Mathematical Statistician, Scientific Computing Coordinator
  • FDA, United States
Matt  Austin, MS


Matt Austin, MS

  • Executive Director, Data Science
  • Amgen, United States
Joan  Buenconsejo, PhD, MPH


Joan Buenconsejo, PhD, MPH

  • Head of Cardiovascular and Early Development Biostatistics
  • Bristol Myers Squibb, United States